المؤلفون: Ann Tivey, Prerana Huddar, Rohan Shotton, Paul Lorigan, Susanna Daniels, Rebecca Lee, Imogen Cheese

المصدر: Tivey, A, Huddar, P, Shotton, R, Cheese, I, Daniels, S, Lorigan, P & J Lee, R 2021, ' Patient engagement in melanoma research: from bench to bedside ', Future Oncology, vol. 17, no. 28, pp. 3705-3716 . https://doi.org/10.2217/fon-2020-1165Test

مصطلحات موضوعية: Cancer Research, 2019-20 coronavirus outbreak, Biomedical Research, PPI, Population, Patient engagement, Patient Advocacy, Patient advocacy, 03 medical and health sciences, 0302 clinical medicine, melanoma, Humans, Medicine, 030212 general & internal medicine, education, Melanoma, risk, advocacy, Clinical Trials as Topic, Medical education, education.field_of_study, research, Informed Consent, patient engagement, Manchester Cancer Research Centre, Information Dissemination, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Patient Selection, clinical trial, General Medicine, Public involvement, Research process, Bench to bedside, Clinical trial, Oncology, Research Design, 030220 oncology & carcinogenesis, Patient Participation, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3974984cf321bb7fa3f4933c034e673Test
https://doi.org/10.2217/fon-2020-1165Test

المؤلفون: C. Blank, Karijn P M Suijkerbuijk, Karlijn de Joode, Adriana Hepner, Céleste Lebbé, Yanina J L Jansen, Elisabeth G.E. de Vries, Andrew Haydon, Claudia Trojaniello, Lucy Storey, Paul Lorigan, Lauren Julia Brown, Alexander M. Menzies, Joanna Mangana, Astrid Aplonia Maria Van Der Veldt, Shahneen Sandhu, Bart Neyns, Douglas B. Johnson, Ellen Kapiteijn, Lisa Zimmer, Matteo S. Carlino, Georgina V. Long, Alison Weppler, Anne M. Hendriks, Harm van Tinteren, Judith M. Versluis, Mathilde Jalving, Victoria Atkinson, Prachi Bhave, Paolo A. Ascierto, Clara Allayous

المساهمون: Surgery, Faculty of Medicine and Pharmacy, Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON)

المصدر: European Journal of Cancer, 151, 72-83. Elsevier Ltd.
European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD
Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003Test
European Journal of Cancer, 151, 72-83. ELSEVIER

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Systemic therapy, 0302 clinical medicine, Stable Disease, Risk Factors, METASTATIC MELANOMA, Immune Checkpoint Inhibitors, Melanoma, OUTCOMES, Manchester Cancer Research Centre, Progression-free survival, Radiotherapy Dosage, Middle Aged, Progression-Free Survival, Europe, 030220 oncology & carcinogenesis, Disease Progression, SURVIVAL, Female, Immune checkpoint inhibition, medicine.symptom, medicine.medical_specialty, Oligoprogression, Metastatic melanoma, Lesion, Solitary progression, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, IMMUNOTHERAPY, Aged, Neoplasm Staging, Retrospective Studies, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Australia, Metastasectomy, Immunotherapy, medicine.disease, United States, Immune checkpoint, Treatment, METASTASES, 030104 developmental biology, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5670859b7c5acf15c6f3031b69510901Test
https://doi.org/10.1016/j.ejca.2021.04.003Test

المؤلفون: Richard Marais, Grazia Saturno, Robert McLeary, Cyril Fisher, Udai Banerji, Alfonso Zambon, Lawrence Davies, Rebecca Lee, J.M.G. Larkin, Natasha Preece, Emma Dean, Paul Lorigan, Dan Niculescu-Duvaz, Matthew G Krebs, Amaya Viros, Nathalie Dhomen, Malin Pedersen, L. Johnson, Filipa Lopes, Caroline J. Springer, D. Holovanchuk, M. E. Gore, Ion Niculescu-Duvaz

المصدر: Annals of Oncology
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483Test

مصطلحات موضوعية: 0301 basic medicine, Drug, Lung Neoplasms, media_common.quotation_subject, Phases of clinical research, medicine.disease_cause, NSCLC, CRC, KRAS, panRAF/SRC inhibitor, PDAC, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Mice, 0302 clinical medicine, Pancreatic tumor, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Medicine, Animals, Humans, Src family kinase, Protein Kinase Inhibitors, media_common, Cell Proliferation, business.industry, Kinase, Hematology, medicine.disease, digestive system diseases, 030104 developmental biology, src-Family Kinases, Oncology, 030220 oncology & carcinogenesis, Mutation, Cancer research, Original Article, Spindle cell sarcoma, business, Proto-oncogene tyrosine-protein kinase Src

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9dd4c81e95c2a5d81da34368a411222Test
http://europepmc.org/articles/PMC7839839Test

المؤلفون: Vanna Chiarion-Sileni, Pablo Luis Ortiz Romero, Daniil Stroyakovskiy, Rosalie Fisher, Alexander M.M. Eggermont, James Larkin, Paul Lorigan, Axel Hauschild, Micaela Hernberg, Mario Mandalà, Alexander J C van Akkooi, Michal Kicinski, Susana Puig, Nageatte Ibrahim, Lars Bastholt, Victoria Atkinson, Peter Hersey, Pietro Quaglino, Shahneen Sandhu, Christian U. Blank, Georgina V. Long, Anna Maria Di Giacomo, Andrey Meshcheryakov, Naoya Yamazaki, Stefan Suciu, Sandrine Marreaud, Peter Mohr, Ragini R. Kudchadkar, Inge Marie Svane, Matthew Strother, Clemens Krepler, Caroline Robert, Paola Queirolo, Catherine Barrow

المساهمون: HUS Comprehensive Cancer Center, Clinicum, Department of Oncology

المصدر: Eggermont, A MM, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A CJ, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, 3122 Cancers, ADJUVANT IPILIMUMAB, MULTICENTER, Pembrolizumab, Placebo, Gastroenterology, 03 medical and health sciences, DOUBLE-BLIND, 0302 clinical medicine, Internal medicine, Medicine, 030212 general & internal medicine, Adverse effect, Melanoma, anti–PD-1, Salvage treatment, Manchester Cancer Research Centre, business.industry, Incidence (epidemiology), ResearchInstitutes_Networks_Beacons/mcrc, NIVOLUMAB, Evaluable Disease, medicine.disease, Confidence interval, 3. Good health, NODE-POSITIVE MELANOMA, Oncology, 030220 oncology & carcinogenesis, SURVIVAL, anti-PD-1, Nivolumab, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206bf54251ce7ab0bcaf3dc33467c927Test
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdfTest

المؤلفون: Paul Lorigan, Tamer Al-Sayed, Tim Cooksley, Avinash Gupta

المصدر: European Journal of Cancer. 130:193-197

مصطلحات موضوعية: Adult, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Immune checkpoint inhibitors, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Acute care, medicine, Humans, Prospective Studies, Colitis, Aged, Pneumonitis, Aged, 80 and over, Hepatitis, business.industry, Antibodies, Monoclonal, Cancer, Middle Aged, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Toxicity, Immunotherapy, Presentation (obstetrics), Emergency Service, Hospital, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::063e61a739ea3b13d22405b3ce60eb8cTest
https://doi.org/10.1016/j.ejca.2020.02.025Test

المؤلفون: Philippa Middlehurst, Nathalie Dhomen, Richard Marais, Gabriela Gremel, John Weightman, Sarah Mills, Jeff Barry, Zena Salih, Avinash Gupta, Elena Galvani, Joshua Tweedy, Paul Lorigan, Antonia Banyard, Piyushkumar A. Mundra, Franziska Baenke, Sara Valpione

المصدر: Nature cancer
Valpione, S, Galvani, E, Tweedy, J, Mundra, P A, Banyard, A, Middlehurst, P, Barry, J, Mills, S, Salih, Z, Weightman, J, Gupta, A, Gremel, G, Baenke, F, Dhomen, N, Lorigan, P C & Marais, R 2020, ' Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy ', Nature Cancer . https://doi.org/10.1038/s43018-019-0022-xTest

مصطلحات موضوعية: Cancer Research, medicine.medical_treatment, T cell, Receptors, Antigen, T-Cell, Peripheral blood mononuclear cell, Article, 03 medical and health sciences, 0302 clinical medicine, Immune system, medicine, Humans, Immunologic Factors, Melanoma, 030304 developmental biology, 0303 health sciences, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, T-cell receptor, Immunotherapy, medicine.disease, 3. Good health, Peripheral, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Immunology, Leukocytes, Mononuclear, Skin cancer, business

وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a54ef2b0dc1631afba50d0992b93beecTest
https://doi.org/10.1038/s43018-019-0022-xTest

المؤلفون: Paul Lorigan, Rohit Thakur, Miles C. Andrews, Kate Hogan, Piyushkumar A. Mundra, Richard Marais, Martin G. Cook, Kang Zeng, Louis Boon, Antonia Banyard, Nathalie Dhomen, Matthew Smith, Jennifer A. Wargo, Jonathan Greenall, Elena Galvani, Garry Ashton, A. Mandal, Beth A. Helmink, Pablo Garcia-Martinez, Gabriela Gremel, Christopher P. E. Chester, Sara Valpione

المصدر: Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Galvani, E, Mundra, P A, Valpione, S, Garcia-Martinez, P, Smith, M, Greenall, J, Thakur, R, Helmink, B, Andrews, M C, Boon, L, Chester, C, Gremel, G, Hogan, K, Mandal, A, Zeng, K, Banyard, A, Ashton, G, Cook, M, Lorigan, P, Wargo, J A, Dhomen, N & Marais, R 2020, ' Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma ', Nature Communications, vol. 11, no. 1, pp. 853 . https://doi.org/10.1038/s41467-020-14632-2Test
Nature Communications

مصطلحات موضوعية: 0301 basic medicine, CD4-Positive T-Lymphocytes, medicine.medical_treatment, Science, Cell, Programmed Cell Death 1 Receptor, General Physics and Astronomy, Cancer immunotherapy, CD8-Positive T-Lymphocytes, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, Mice, 0302 clinical medicine, Stroma, Medicine, Animals, Humans, Exome, Cancer models, lcsh:Science, Melanoma, Cell Proliferation, Multidisciplinary, Manchester Cancer Research Centre, business.industry, Cell growth, ResearchInstitutes_Networks_Beacons/mcrc, General Chemistry, Immunotherapy, medicine.disease, Immune checkpoint, 3. Good health, Blockade, Disease Models, Animal, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer research, Female, lcsh:Q, Stromal Cells, business, Cell Division

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::556e5bce3c32f9fe3828bc8a54567eafTest
http://link.springer.com/article/10.1038/s41467-020-14632-2Test

المؤلفون: Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan

المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology

المصدر: Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38, 33, pp. 3925-3936

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
https://hdl.handle.net/2066/228545Test

المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin

المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test

المؤلفون: Piyushkumar A. Mundra, Luca Giovanni Campana, John Weightman, Sara Valpione, Francesco De Rosa, Nathalie Dhomen, Sarah Mills, Avinash Gupta, Richard Marais, Elena Galvani, Paul Lorigan

المصدر: Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)

مصطلحات موضوعية: 0301 basic medicine, Statistical methods, Science, T cell, medicine.medical_treatment, General Physics and Astronomy, chemical and pharmacologic phenomena, Cancer immunotherapy, Predictive markers, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, 0302 clinical medicine, Immune system, Antigen, medicine, Multidisciplinary, business.industry, Melanoma, T-cell receptor, Cancer, General Chemistry, Immunotherapy, medicine.disease, 3. Good health, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer research, Tumour immunology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27708f9660b4ad51b52f508185a0af2cTest
http://europepmc.org/articles/PMC8253860Test